Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

FASEB Journal

Volumn 25, Issue 7, 2011, Pages 2433-2446

  Vaneycken, Ilse ^a   Devoogdt, Nick ^a   Van Gassen, Naomi ^a,c   Vincke, Cécile ^a,c   Xavier, Catarina ^a   Wernery, Ulrich ^d   Muyldermans, Serge ^a,c   Lahoutte, Tony ^a,b   Caveliers, Vicky ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d CENTRAL VETERINARY RESEARCH LABORATORY   (United Arab Emirates)

Author keywords

SPECT; Tracer development

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOBODY; PERTUZUMAB; RADIOLIGAND; TECHNETIUM 99M; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUDE MOUSE; PHAGE DISPLAY; PRIORITY JOURNAL; SCREENING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE PLASMON RESONANCE; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CAMELIDS, NEW WORLD; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MOLECULAR IMAGING; PEPTIDE LIBRARY; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS; X-RAY MICROTOMOGRAPHY;

CAMELUS DROMEDARIUS;

EID: 79960188481     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-180331     Document Type: Article

References (34)

1. Boyle, P. and Ferlay, J. (2005) Cancer incidence and mortality in Europe, 2004. Annals Oncol. 16, 481-488 (Pubitemid 40458328)
2. Mendelsohn, J., Howley, P. M., Israel, M. A., Gray, J. W., and Thompson, C. B. (2008) The Molecular Basis of Cancer. Saunders, Elsevier, Philadelphia
3. Yarden, Y. (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2), 1-13
4. Hicks, D. G., and Kulkarni, S. (2008) HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129, 263-273 (Pubitemid 352029317)
5. Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., Kelsey, S. M., and Fyfe, G. (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23, 2534-2543 (Pubitemid 47050843)
6. Zidan, J., Dashkovsky, I., Stayerman, C., Basher, W., Cozacov, C., and Hadary, A. (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Brit. J. Cancer 93, 552-556 (Pubitemid 43079998)
7. Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhelst, A., Bernard-Marty, C., Piccart, M. J., and Larsimont, D. (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Annals Oncol. 13, 1036-1043
8. Hanna, W., Nofech-Mozes, S., and Kahn, H. J. (2007) Intratumoral heterogeneity of HER2/neu in breast cancer - a rare event. Breast J. 13, 122-129 (Pubitemid 46280606)
9. Tolmachev, V. (2008) Imaging of HER-2 overexpression in tumors for guiding therapy. Curr. Pharm. Des. 14, 2999-3019
10. Behr, T. M., Behe, M., Angerstein, C., Griesinger, F., Kaufmann, C. C., Wörmann, B., Emons, G., and Becker, W. (2001) Does immunoscintigraphy allow for prognostic predictions with respect to the toxicity and therapeutic efficacy of herceptin immunotherapy of metastatic breast cancer? Eur. J. Nucl. Med. 28, 976
11. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J. Nucl. Med. 50, 417-425
12. Willuda, J., Honegger, A., Waibel, R., Schubiger, P. A., Stahel, R., Zangemeister-Wittke, U., and Plückthun, A. (1999) High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized antiepithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 59, 5758-5767
13. Whitlow, M., Bella, B. A., Feng, S. L., Filpula, D., Hardman, K. D, Hubert, S. L., Rollence, M. L., Wood, J. F., Schott, M. E., Milenic, D. E., Yokota, T., and Schlom, J. (1993) An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 6, 989-995 (Pubitemid 23347376)
14. Cortez-Retamozo, V., Lahoutte, T., Caveliers, V., Gainkam, L. O. T., Hernot, S., Packeu, A., De Vos, F., Vanhove, C., Muyldermans, S., De Baetselier, P., and Revets, H. (2008) 99mTc-labeled nanobodies: a new type of targeted probes for imaging antigen expression. Curr. Radiopharmaceut. 1, 37-41
15. 99mTc-labeled EGFR specific nanobody for in vivo monitoring of EGFR expression. Mol. Imag. Biol. 10, 167-175
16. Gainkam, L. O. T., Huang, L., Caveliers, V., Keyaerts, M., Hernot, S., Vaneycken, I., Vanhove, C., Revets, H., De Baetselier, P., and Lahoutte, T. (2008) Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/microCT. J. Nucl. Med. 49, 788-795 (Pubitemid 351717545)
17. Vaneycken, I., Govaert, J., Vincke, C., Caveliers, V., Lahoutte, T., De Baetselier, P., Raes, G., Bossuyt, A., Muyldermans, S., and Devoogdt, N. (2010) In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J. Nucl. Med. 51, 1099-1106
18. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., and Hamers, R. (1993) Naturally occurring antibodies devoid of light chains. Nature 363, 446-448 (Pubitemid 23179389)
19. Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., and Muyldermans, S. (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414, 521-526 (Pubitemid 27390659)
20. Saerens, D., Pellis, M., Loris. R., Pardon E, Dumoulin, M., Matagne, A., Wyns, L., Muyldermans, S., and Conrath, K. (2005) Identification of a universal VHH framework to graft noncanonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol. 352, 597-607 (Pubitemid 41225471)
21. Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., and Conrath, K. (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284, 3273-3284
22. McLarty, K., Fasih, A., Scollard, D. A., Done, S. J., Vines, D. C., Green, D. E., Costantini, D. L., and Reilly, R. M. (2009) 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J. Nucl. Med. 50, 1848-1856
23. Tang, Y., Scollard, D., Chen, P., Wang, J., Holloway, C., and Reilly, R. M. (2005) Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (herceptin) Fab fragments. Nucl. Med. Commun. 26, 427-432
24. Nielsen, U. B., Adams, G. P., Weiner, L. M., and Marks, J. D. (2000) Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60, 6434-6440
25. Robinson, M. K., Doss, M., Shaller, C., Narayanan, D., Marks, J. D., Adler, L. P., González Trotter, D. E., and Adams, G. P. (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 65, 1471-1478 (Pubitemid 40270176)
26. Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy-Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., and Plückthun, A. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 70, 1595-1605
27. Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., and Weiner, L. M. (2001) High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750-4755
28. Ahlgren, S., Orlova, A., Wållberg, H., Hansson, M., Sandström, M., Lewsley, R., Wennborg, A., Abrahmsén, L., Tolmachev, V., and Feldwisch, J. (2010) Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J. Nucl. Med. 51, 1131-1138
29. Harmsen, M. M., and De Haard, H. J. (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77, 13-22 (Pubitemid 47573319)
30. Gainkam, L. O. T., Caveliers, V., Devoogdt, N., Vanhove, C., Xavier, C., Boerman, O., Muyldermans, S., Bossuyt, A., and Lahoutte, T. (2010) Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. [E-pub ahead of print] Contrast Media Mol. Imaging doi: 10.1002/cmmi.408
31. De Groeve, K., Deschacht, N., De Koninck, C., Caveliers, V., Lahoutte, T., Devoogdt, N., Muyldermans, S., De Baetselier, P., and Raes, G. (2010) Nanobodies as tools for in vivo imaging of specific immune cell types. J. Nucl. Med. 51, 782-789
32. Zahnd, C., Pecorari, F., Straumann, N., Wyler, E., and Plückthun, A. (2006) Selection and characterization of Her2 bindingdesigned ankyrin repeat proteins. J. Biol. Chem. 281, 35167-35175 (Pubitemid 46036556)
33. Orlova, A., Magnusson, M., Eriksson, T. L., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., Nilsson, F. Y. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66, 4339-4348
34. Vegt, E., de Jong, M., Wetzels, J. F., Masereeuw, R., Melis, M., Oyen, W. J., Gotthardt, M., Boerman, O. C. (2010) Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med. 51, 1049-1058